News & Updates

The novel oral, non-peptide glucagon-like peptide-1 receptor agonist (GLP-1 RA) orforglipron gains the upper hand over the current leading oral GLP-1 RA, semaglutide, in individuals with type 2 diabetes (T2D) inadequately controlled on metformin in the phase III ACHIEVE-3 study.

Recurrent urinary tract infection (UTI) care in primary and secondary care settings appears to be characterized by low guideline adherence, with a substantial number of women still being treated with antibiotics and subjected to low-yield investigations, according to a study.

In the treatment of overactive bladder (OAB) in children, mirabegron demonstrates efficacy similar to that of solifenacin but has a better safety profile, according to a meta-analysis presented at the annual EAU Congress.

Combination treatment with phentermine-topiramate extended release (ER) and a digitally enhanced lifestyle intervention (DELI) results in a significant and sustained weight reduction, as well as a decrease in cardiovascular disease (CVD) risk, in adults with obesity, reports a study.

Patients with noncentre point-involving geographic atrophy (GA) who receive avacincaptad pegol (ACP) 2 mg every month (EM) or every other month (EOM) show a persistent decrease in GA growth over 2 years relative to sham therapy, with no new safety signals, according to the GATHER2 study.